报价延迟最少15分钟:2026/01/09 11:22 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
12.51 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.01/-3.85
|
|
企业价值
63.13M
|
| 资产负债 |
|
每股账面净值
-2.88
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. |
